An international supplier of specialist
plastic, fibre and foam products with four principle operating divisions –
component & protection solutions, porous technologies, coated and security
products and filter products. I have no holding in this company (epic code: ESNT). Previously known as Filtrona (epic code: ESNT)
Market/Index
|
Full/FTSE 250
|
Industry
|
Food & Tobacco
|
Sales
|
£663.4m
|
Earnings
|
£52.2m
|
Market Cap
|
£1.57bn
|
Share Price
|
741p
|
Norm. EPS
|
27.6p
|
Historic P/E
|
26.9
|
Est. 2013 growth
|
32.3%
|
Prospective P/E
|
20.3
|
Est. 2014 growth
|
15.9%
|
Prospective P/E
|
17.5
|
Rolling PEG
|
0.77
|
SGR
|
11.6%
|
PBV
|
6.67
|
Historic Yield
|
1.69%
|
ROE
|
23.6%
|
Operating Margin
|
13.0%
|
5 yr BV + Div return
|
19.3%
|
5 yr FCF return on BV
|
21.7%
|
This is the fourth company from the growth
screen and was formerly part of Bunzl plc, demerging in June 2005 to became a
separately listed company. Many people will know them as the supplier of filters
to the cigarette market, although today this represents less than 36% of sales
and less than 25% of operating profit.
Many on the executive board have been with
Filtrona for some time, with the notable exception of the CEO Colin Day, who
joined in April 2011 from Reckitt Benckiser where he had been CFO for 10
years. Day had a good reputation at
Reckitt Benckiser and during his tenure grew earnings by 18% pa and oversaw a
share price rise of 15% pa.
Filtrona are an acquisitive company, with
their most recent purchase completed this month for Contego Healthcare,
specialising in plastic fibre & foam products to the pharmaceutical and healthcare
market at a price of £160m (11.5x operating profit). They financed this purchase through a placing,
issuing an additional 9.99% of their then issued shares.
Filtrona earn good operating margins and a
healthy return on equity, demonstrating that there are probably high barriers
to entry to their various market niches.
It is worth noting though that operating margins did decline slightly
last year by 40 basis points and free cash flow (FCF) at £31m was substantially
less than 2011’s £50m. This FCF decline
was due to a much higher spend on capital expenditure that was double the rate
of depreciation, leaving one to assume that much of this higher spend was due
to expenditure on expansion. An example
of this is Moss, Skiffy and Alliance their US based Component Distribution
business, that opened a new office, plant and warehouse in Houston, doubling
the size of the facility to underpin future potential growth. Consequently net debt has increased from £144.9m
in 2011 to £163.5m in 2012 resulting in net gearing of almost 70%, although
interest cover is strong at 8.2x and debt/EBITDA at 1.39 and operating cash
flow/debt of 45.3% are acceptable.
Their 5 year return on book value is
respectable in both terms of earnings and cash, demonstrating both good
conversion of profits into cash and improved shareholder value.
Filtrona has an estimated weighted average
cost of capital of 8.6% and earn a good average return on their capital
employed of 23%; the wider this gap the higher economic return that
shareholders will experience and Filtrona perform well in this respect.
Filtrona though is an expensive share at
26.9x historic earnings and 20.3x this year and you will be paying almost 7x
book value. For that though you receive
an investment in a well run company that produces good returns, well in excess
of their cost of capital. On a
discounted cash flow basis Filtrona have a fair value of about 700p, using a
cost of equity of 11.6% and free cash flow (FCF) growth of 20% over the next
two years, 15% for the following 8 years and 2.5% in perpetuity. I have assumed
a starting sustainable FCF of £50m (similar to 2011, rather than the depressed
2012 number).
In summary Filtrona is a high quality growth
company, run by a fairly new CEO with a strong track record from the past, but they are
currently fully valued.